Ideaya exits Werner and Pol theta
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
MAT2A inhibition gets another endorsement
Gilead opting against IDE397 is still good news for Ideaya.
Insilico still feels the need for TEAD
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
Ideaya socks it to GSK
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.
